Nuvilex (NASDAQ:PMCB) Stock Price Down 1.8% – Time to Sell?

Nuvilex Inc. (NASDAQ:PMCB)’s stock price was down 1.8% on Monday . The stock traded as low as $0.6740 and last traded at $0.69. Approximately 204,167 shares changed hands during trading, an increase of 8% from the average daily volume of 189,682 shares. The stock had previously closed at $0.7025.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PMCB. Wall Street Zen raised Nuvilex to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Nuvilex Stock Performance

The company has a market capitalization of $6.99 million, a price-to-earnings ratio of -0.50 and a beta of 0.39. The firm has a fifty day moving average price of $0.80 and a 200-day moving average price of $0.89.

Nuvilex (NASDAQ:PMCB) last posted its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

Insider Transactions at Nuvilex

In other news, CEO Joshua Silverman acquired 40,000 shares of the stock in a transaction on Wednesday, January 7th. The stock was acquired at an average cost of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the transaction, the chief executive officer directly owned 416,250 shares in the company, valued at approximately $345,487.50. This trade represents a 10.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have purchased 110,000 shares of company stock valued at $89,000 over the last quarter. Company insiders own 10.33% of the company’s stock.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.